Sign in3 stories
The retinal disease company said patient dosing is underway in its Phase 1b/2 study of TH103, with cash of $93.5 million expected to fund operations into the fourth quarter of 2027.
SEC filing
The Nasdaq company also disclosed the resignation of its chief accounting officer and named an interim replacement, per a filing dated July 20, 2026.
SEC filing
The company said additional patients in expanded cohorts showed sustained vision, anatomy, and pharmacokinetic benefits, with Phase 1b/2 data still expected in the first half of 2027.
SEC filing